Research area
Health & Longevity
Human health, disease, treatment and aging. The largest corpus area supports distinct cancer, neurological and therapeutic navigation.
-
Evidence date ·Why is EA5181 testing durvalumab earlier in treatment?
Review or Meta-AnalysisTracked over timeEarlier trials reported 38%–46% local failure after chemoradiation. A 2022 review explains why EA5181 tests adding durvalumab during treatment.
-
Evidence date ·How lung inflammation rates varied in stage III lung cancer studies
Review or Meta-AnalysisTracked over timeIn a 13-study review, clinical trials reported grade 2 lung inflammation rates of 23% when immune therapy overlapped chemoradiation and 11% when it followed.
-
Evidence date ·Why did immunotherapy draw interest in advanced or treatment-resistant digestive cancers?
Review or Meta-AnalysisA 2021 review explains why directing immune activity toward tumor features seemed promising for digestive cancers that had spread or resisted initial treatment.
-
Evidence date ·What checkpoint inhibitor evidence says about older adults with poorer function
Review or Meta-AnalysisA 2021 review found support for checkpoint inhibitors in older adults with advanced lung cancer, but evidence for those with poorer function remains limited.
-
Evidence date ·Why can skin lymphoma weaken defenses against infection and the cancer itself?
Review or Meta-AnalysisA 2021 review traces how advanced skin lymphoma weakens defenses against infection and the tumor, and why restoring immunity has become a treatment goal.
-
Evidence date ·How did CD40 activation affect precancerous mouth lesions in mice?
Peer-Reviewed PaperIn mice with precancerous mouth lesions, activating CD40 reduced progression to cancer more than the other tested approaches and was linked to distinct immune-cell changes.
-
Evidence date ·How doctors weighed COVID-19 danger against timely lung cancer care
Review or Meta-AnalysisIn one registry, 61 of 237 people with lung cancer and COVID-19 died. A 2021 review explains why delaying cancer care also carried risks.
-
Evidence date ·What can Merkel cell carcinoma’s viral or ultraviolet origin reveal about outlook?
Review or Meta-AnalysisA 2021 review reports a more favorable outlook for virus-linked Merkel cell tumors than for tumors tied to ultraviolet-induced genetic damage.
-
Evidence date ·Why adding an immune drug did not settle the chemotherapy choice
Review or Meta-AnalysisPooled immune-drug combinations showed better survival than platinum-etoposide in a 10-trial review; an indirect comparison with platinum-irinotecan found no clear edge.
-
Evidence date ·What can kidney inflammation during cancer care mean?
Review or Meta-AnalysisA 2021 oncology review compares drug-related kidney inflammation with infection and cancer-cell infiltration, showing why the cause can change care.